Health-related utility values of patients with primary Sjogren's syndrome and its predictors

Dennis Lendrem; Sheryl Mitchell; Peter McMeekin; Simon Bowman; Elizabeth Price; Colin Pease; Paul Emery; Jacqueline Andrews; Peter Lanyon; John Hunter; Monica Gupta; Michele Bombardieri; Nurhan Sutcliffe; Costantino Pitzalis; John McLaren; Annie Cooper; Marian Regan; Ian Giles; David Isenberg; Saravanan Vadivelu; David Coady; Bhaskar Dasgupta; Neil McHugh; Steven Young-Min; Robert Moots; Nagui Gendi; Mohammed Akil; Bridget Griffiths; Wan-Fai Ng

doi:10.1136/annrheumdis-2012-202863

Health-related utility values of patients with primary Sjogren's syndrome and its predictors

Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, Simon Bowman, Elizabeth Price, Colin Pease, Paul Emery, Jacqueline Andrews, Peter Lanyon, John Hunter, Monica Gupta, Michele Bombardieri, Nurhan Sutcliffe, Costantino Pitzalis, John McLaren, Annie Cooper, Marian Regan, Ian Giles, David Isenberg, Saravanan VadiveluDavid Coady, Bhaskar Dasgupta, Neil McHugh, Steven Young-Min, Robert Moots, Nagui Gendi, Mohammed Akil, Bridget Griffiths, Wan-Fai Ng

Nursing Midwifery and Health Department

Research output: Contribution to journal › Article › peer-review

103 Citations (Scopus)

Abstract

Objectives - EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK.
Methods - Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored.
Results - The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability.

Conclusions - This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.

Original language	English
Pages (from-to)	1362-1368
Journal	Annals of the Rheumatic Diseases
Volume	73
Issue number	7
Early online date	6 Jun 2014
DOIs	https://doi.org/10.1136/annrheumdis-2012-202863
Publication status	Published - 12 Jun 2014

Access to Document

10.1136/annrheumdis-2012-202863

Cite this

Lendrem, D., Mitchell, S., McMeekin, P., Bowman, S., Price, E., Pease, C., Emery, P., Andrews, J., Lanyon, P., Hunter, J., Gupta, M., Bombardieri, M., Sutcliffe, N., Pitzalis, C., McLaren, J., Cooper, A., Regan, M., Giles, I., Isenberg, D., ... Ng, W.-F. (2014). Health-related utility values of patients with primary Sjogren's syndrome and its predictors. Annals of the Rheumatic Diseases, 73(7), 1362-1368. https://doi.org/10.1136/annrheumdis-2012-202863

@article{74d030c8cece421aaca6851865b02af9,

title = "Health-related utility values of patients with primary Sjogren's syndrome and its predictors",

abstract = "Objectives - EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sj{\"o}gren's syndrome (PSS) in the UK.Methods - Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored.Results - The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability.Conclusions - This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.",

author = "Dennis Lendrem and Sheryl Mitchell and Peter McMeekin and Simon Bowman and Elizabeth Price and Colin Pease and Paul Emery and Jacqueline Andrews and Peter Lanyon and John Hunter and Monica Gupta and Michele Bombardieri and Nurhan Sutcliffe and Costantino Pitzalis and John McLaren and Annie Cooper and Marian Regan and Ian Giles and David Isenberg and Saravanan Vadivelu and David Coady and Bhaskar Dasgupta and Neil McHugh and Steven Young-Min and Robert Moots and Nagui Gendi and Mohammed Akil and Bridget Griffiths and Wan-Fai Ng",

year = "2014",

month = jun,

day = "12",

doi = "10.1136/annrheumdis-2012-202863",

language = "English",

volume = "73",

pages = "1362--1368",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ",

number = "7",

}

Lendrem, D, Mitchell, S, McMeekin, P, Bowman, S, Price, E, Pease, C, Emery, P, Andrews, J, Lanyon, P, Hunter, J, Gupta, M, Bombardieri, M, Sutcliffe, N, Pitzalis, C, McLaren, J, Cooper, A, Regan, M, Giles, I, Isenberg, D, Vadivelu, S, Coady, D, Dasgupta, B, McHugh, N, Young-Min, S, Moots, R, Gendi, N, Akil, M, Griffiths, B & Ng, W-F 2014, 'Health-related utility values of patients with primary Sjogren's syndrome and its predictors', Annals of the Rheumatic Diseases, vol. 73, no. 7, pp. 1362-1368. https://doi.org/10.1136/annrheumdis-2012-202863

TY - JOUR

T1 - Health-related utility values of patients with primary Sjogren's syndrome and its predictors

AU - Lendrem, Dennis

AU - Mitchell, Sheryl

AU - McMeekin, Peter

AU - Bowman, Simon

AU - Price, Elizabeth

AU - Pease, Colin

AU - Emery, Paul

AU - Andrews, Jacqueline

AU - Lanyon, Peter

AU - Hunter, John

AU - Gupta, Monica

AU - Bombardieri, Michele

AU - Sutcliffe, Nurhan

AU - Pitzalis, Costantino

AU - McLaren, John

AU - Cooper, Annie

AU - Regan, Marian

AU - Giles, Ian

AU - Isenberg, David

AU - Vadivelu, Saravanan

AU - Coady, David

AU - Dasgupta, Bhaskar

AU - McHugh, Neil

AU - Young-Min, Steven

AU - Moots, Robert

AU - Gendi, Nagui

AU - Akil, Mohammed

AU - Griffiths, Bridget

AU - Ng, Wan-Fai

PY - 2014/6/12

Y1 - 2014/6/12

N2 - Objectives - EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK.Methods - Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored.Results - The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability.Conclusions - This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.

AB - Objectives - EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK.Methods - Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored.Results - The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability.Conclusions - This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.

U2 - 10.1136/annrheumdis-2012-202863

DO - 10.1136/annrheumdis-2012-202863

M3 - Article

SN - 0003-4967

VL - 73

SP - 1362

EP - 1368

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 7

ER -

Health-related utility values of patients with primary Sjogren's syndrome and its predictors

Abstract

Access to Document

Fingerprint

Cite this